Nova Eye Medical (AU:EYE) has released an update.
Nova Eye Medical reports a robust year in their Glaucoma Segment with a 37% year-on-year revenue growth, reaching A$27.7 million in the second half of FY24. The U.S. market saw a 73% increase in sales, contributing to the company’s fourth consecutive half-year of growth, with expectations of a significant improvement in second half operating results. Strategic expansion in the U.S. with additional field sales specialists has been credited for the improved sales and market coverage.
For further insights into AU:EYE stock, check out TipRanks’ Stock Analysis page.
